NCT03872661 2026-04-21
NIBCUN
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06688656 2024-11-14
Peri-E
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT05400070 2024-10-18
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Tang-Du Hospital
Phase 2 Active not recruiting
NCT06421298 2024-05-20
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
Beijing Chest Hospital, Capital Medical University
Phase 2 Recruiting
NCT04790409 2023-09-14
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Zhejiang Cancer Hospital
Phase 2 Completed
NCT04513301 2020-08-14
Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study
Shanghai Cancer Hospital, China
Phase 2 Unknown
NCT04486287 2020-07-24
Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04189094 2019-12-06
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03765775 2018-12-06
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
First Hospital of Shijiazhuang City
Phase 2 Unknown